New insider Cavorsi Robert claimed ownership of 140,083 shares (SEC Form 3)
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 04/19/2024 |
3. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Class A Common Stock | 23,579(2) | D | |
| Class A Common Stock(1) | 739(3) | D | |
| Class A Common Stock(1) | 215(3) | D | |
| Class A Common Stock(1) | 2,163(4) | D | |
| Class A Common Stock(1) | 4,203(5) | D | |
| Class A Common Stock(1) | 51,750(6) | D | |
| Class A Common Stock(1) | 57,434(7) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (8) | 03/09/2031 | Class A Common Stock | 6,519 | $15.63 | D | |
| Stock Option (Right to Buy) | (9) | 07/16/2031 | Class A Common Stock | 32,559 | $14.45 | D | |
| Stock Option (Right to Buy) | (10) | 03/01/2032 | Class A Common Stock | 19,935 | $8.03 | D | |
| Stock Option (Right to Buy) | (11) | 03/15/2033 | Class A Common Stock | 81,000 | $2.51 | D | |
| Stock Option (Right to Buy) | (12) | 02/21/2034 | Class A Common Stock | 103,842 | $3.43 | D | |
| Explanation of Responses: |
| 1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. |
| 2. Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan. |
| 3. The RSUs vest in equal annual installments over four years beginning March 9, 2021, and shall become fully vested on March 9, 2025. |
| 4. The RSUs vest in equal annual installments over four years beginning July 16, 2021, and shall become fully vested on July 16, 2025. |
| 5. The RSUs vest in equal annual installments over four years beginning March 1, 2022, and shall become fully vested on March 1, 2026. |
| 6. The RSUs vest in equal annual installments over four years beginning February 15, 2023, and shall become fully vested on February 15, 2027. |
| 7. The RSUs vest in equal annual installments over four years beginning February 15, 2024, and shall become fully vested on February 15, 2028. |
| 8. The option becomes exercisable in equal annual installments over four years beginning March 9, 2021, and shall become fully vested and exercisable on March 9, 2025. |
| 9. The option becomes exercisable in equal annual installments over four years beginning July 16, 2021, and shall become fully vested and exercisable on July 16, 2025. |
| 10. The option becomes exercisable in equal annual installments over four years beginning March 1, 2022, and shall become fully vested and exercisable on March 1, 2026. |
| 11. The option becomes exercisable in equal annual installments over four years beginning February 15, 2023, and shall become fully vested and exercisable on February 15, 2027. |
| 12. The option becomes exercisable in equal annual installments over four years beginning February 15, 2024, and shall become fully vested and exercisable on February 15, 2028. |
| Remarks: |
| Exhibit 24 Power of Attorney filed herewith. |
| /s/ William R. Kolb, Attorney-in-Fact | 04/29/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||